导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 6.68% | 754/3266 |
| 近一周 | -1.51% | 1529/3690 |
| 近一月 | -2.67% | 1202/3663 |
| 近一季 | -3.70% | 1156/3534 |
| 近半年 | 4.00% | 636/3357 |
| 近一年 | 10.75% | 753/3056 |
| 近两年 | 52.13% | 1034/2167 |
| 近三年 | 31.38% | 721/1638 |
| 成立以来 | 134.19% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-1.78% 2481/4961 |
16.17% 1591/5312 |
- - |
- - |
| 2025 | 19.11% 2251/4813 |
0.87% 1749/3635 |
2.02% 1939/4076 |
13.52% 2983/4524 |
1.96% 1132/4813 |
| 2024 | 10.79% 1373/3463 |
3.31% 596/2808 |
-0.23% 715/3014 |
9.76% 2669/3129 |
-2.07% 1946/3463 |
| 2023 | -8.56% 1029/2656 |
3.83% 1116/2280 |
-3.82% 914/2385 |
-2.16% 630/2515 |
-6.41% 1759/2655 |
| 2022 | -18.12% 666/2207 |
-11.91% 556/1919 |
6.79% 605/2016 |
-13.08% 829/2113 |
0.14% 1535/2208 |
| 2021 | -0.06% 736/1822 |
0.51% 288/1255 |
6.18% 764/1330 |
-6.14% 901/1466 |
-0.23% 1216/1822 |
| 2020 | 41.38% 292/1250 |
-6.52% 493/1028 |
15.76% 476/1067 |
16.22% 161/1164 |
12.42% 470/1184 |
| 2019 | 43.42% 193/1092 |
24.48% 508/754 |
2.78% 69/804 |
4.60% 191/850 |
7.16% 478/918 |
| 2018 | -22.68% 255/834 |
- - |
- - |
- - |
-11.90% 377/691 |
| 2017 | 14.47% 256/714 |
- - |
- - |
- - |
- - |
| 2016 | -7.25% 211/605 |
- - |
- - |
- - |
- - |
| 2015 | 8.31% 169/575 |
- - |
- - |
- - |
- - |
| 2014 | 47.42% 99/237 |
- - |
- - |
- - |
- - |
| 2013 | -7.72% 129/186 |
- - |
- - |
- - |
- - |
| 2012 | 12.62% 24/140 |
- - |
- - |
- - |
- - |
| 2011 | -22.72% 52/102 |
- - |
- - |
- - |
- - |
| 2010 | -5.89% 16/58 |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 国富沪深300指数增强A VS. 长安沪深300非周期A(740101) |